Stockscreener 앱 받기
14.00
2.94%
0.58
Novocure Ltd 주식(NVCR)의 최신 뉴스
[144] NovoCure Ltd SEC Filing - Stock Titan
NovoCure Ltd. Hits Day Low of $11.80 Amid Price Pressure - Markets Mojo
Vanguard Group Inc. Sells 296,555 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Limited $NVCR Shares Bought by Quantbot Technologies LP - MarketBeat
NovoCure (NVCR) CMO sells shares to cover RSU tax withholding - Stock Titan
NovoCure (NVCR) CHRO sells 1,441 shares in tax withholding trade - Stock Titan
NovoCure (NVCR) COO offloads 1,963 shares in tax sell-to-cover - Stock Titan
Tax-withholding sale of 1,029 NovoCure (NASDAQ: NVCR) shares by ex-CMO - Stock Titan
NovoCure (NVCR) CEO reports RSU vesting and tax-cover share sales - Stock Titan
Equity awards and tax share withholding for NovoCure (NVCR) ex-CEO Cordova - Stock Titan
NovoCure (NASDAQ: NVCR) General Counsel receives 17,755-share performance award - Stock Titan
NovoCure (NVCR) Is Up 24.5% After FDA Approval Of Optune Pax And 2026 Guidance Update - Sahm
FDA Approves Novocure’s Optune Pax Wearable Device for Pancreatic Cancer - Digital Health News
NovoCure Limited 2025 Q4ResultsEarnings Call Presentation (NASDAQ:NVCR) 2026-03-02 - Seeking Alpha
NovoCure Ltd wins Japanese reimbursement approval for lung cancer treatment - Traders Union
Novocure gains Japan reimbursement for Optune Lua device - Investing.com Nigeria
NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Novocure (NVCR) Gains Japanese Reimbursement Approval for Optune Lua - GuruFocus
Novocure (NVCR) Gains Approval for Optune Lua Reimbursement in J - GuruFocus
Novocure gains Japan reimbursement for Optune Lua device By Investing.com - Investing.com India
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer - Yahoo Finance
Equities Analysts Set Expectations for NovoCure Q1 Earnings - MarketBeat
A Look At NovoCure (NVCR) Valuation As Record 2025 Results And Optune Pax Approval Reset Growth Expectations - Yahoo Finance
NovoCure Earnings Call: Growth Builds Amid Profit Strain - TipRanks
NovoCure Shares Gap Down, Weak Start Raises Market Concerns - Markets Mojo
NovoCure Ltd. Hits Day High with 27.68% Surge in Stock Price - Markets Mojo
NovoCure Ltd. Experiences Revision in Stock Evaluation Amidst Market Challenges - Markets Mojo
Is NovoCure (NVCR) Pricing Look Out Of Step With Recent Share Rebound - simplywall.st
NovoCure’s Pancreatic Cancer Approval And New CEO Shift Risk Reward Profile - simplywall.st
Hohimer Wealth Management LLC Takes Position in NovoCure Limited $NVCR - MarketBeat
Novocure to Participate in 2026 Leerink Global Healthcare Conference - Yahoo Finance
NovoCure Limited (NASDAQ:NVCR) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: NovoCure (NVCR) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus
NovoCure (NASDAQ:NVCR) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS - MarketBeat
NovoCure (NVCR) Q4 Loss Narrowing Challenges Bearish Narrative On Persistent Unprofitability - simplywall.st
NovoCure: Q4 Earnings Snapshot - theheraldreview.com
NovoCure Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
NovoCure Ltd (NVCR) Q4 2025 Earnings Call Highlights: Record Rev - GuruFocus
NovoCure Limited Q4 2025 Earnings Call Summary - Yahoo Finance
HC Wainwright & Co. Raises NovoCure (NVCR) Price Target to $49 | - GuruFocus
HC Wainwright Increases NovoCure (NASDAQ:NVCR) Price Target to $49.00 - MarketBeat
NVCR: Novocure Reports Strong Q4 Earnings and FDA Approval Boost - GuruFocus
NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
NovoCure (NASDAQ:NVCR) Shares Gap DownWhat's Next? - MarketBeat
NovoCure's Q4 Net Loss Narrows, Revenue Rises; 2026 Revenue Guidance Issued - marketscreener.com
Novocure reports quarterly and full year results for period ended December 31, 2025 - Traders Union
NovoCure Q4 Earnings Call Highlights - MarketBeat
NOVOCURE ($NVCR) Releases Q4 2025 Earnings - Quiver Quantitative
NovoCure: Fourth Quarter Financial Overview - Bitget
Novocure Ltd earnings beat by $0.19, revenue topped estimates - Investing.com
Novocure (NASDAQ: NVCR) posts 2025 results and wins FDA nod for Optune Pax - Stock Titan
FDA approves Novocure’s Optune Pax for pancreatic cancer as 2025 sales climb - Stock Titan
Assessing NovoCure (NVCR) Valuation After British Columbia’s Reimbursement Breakthrough for TTFields Therapy - simplywall.st
NovoCure (NASDAQ:NVCR) Shares Gap UpShould You Buy? - MarketBeat
Novocure stock jumps after Medicare billing restored - Investing.com South Africa
Novocure earnings up next: Pancreatic cancer launch in focus - Investing.com
Novocure earnings up next: Pancreatic cancer launch in focus By Investing.com - Investing.com South Africa
Novocure Ltd says CMS reinstates Medicare billing privileges retroactivelySEC filing - marketscreener.com
Novocure Ltd Says CMS Reinstates Medicare Billing Privileges RetroactivelySEC Filing - TradingView
CMS reverses Novocure (NASDAQ: NVCR) Medicare billing halt - Stock Titan
BC becomes first province to fund Novocure brain cancer therapy - Stock Titan
1.60%
자본화:
|
볼륨(24시간):